CellType is building an agentic drug company. AI agents that run the full drug discovery pipeline on top of biological foundation models that simulate human biology. Our core technology, developed with Google DeepMind, has already discovered and validated a new cancer treatment signal. We’re working with Top 10 pharma.
Ivan Vrkic
Co-Founder @ CellType (W26). ML @ Yale & EPFL. Building the next-generation agentic drug company. Co-developed our core technology Cell2Sentence at Yale and published at ICML. Previously led large-scale foundation model training at a biotech startup and built software to control CERN's Large Hadron Collider.
David van Dijk
Co-Founder & CEO of CellType (W26). Yale Professor, 11,000+ citations. Built biological foundation models with Google. Building the agentic drug company.
LinkedInDavid van Dijk
Yale professor with over 11,000 citations who has published in Cell, Nature, ICML, and NeurIPS.
Ivan Vrkic
Co-Founder @ CellType (W26). ML @ Yale & EPFL. Building the next-generation agentic drug company. Co-developed our core technology Cell2Sentence at Yale and published at ICML. Previously led large-scale foundation model training at a biotech startup and built software to control CERN's Large Hadron Collider.
LinkedIn
